Associated equity: Oryzon Genomics
Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for haematology-oncology, where the strategic priority is in first-line acute myeloid leukaemia; there is potential for an accelerated approval pathway should clinical data continue to be supportive. It is also being evaluated in other indications, such as myelodysplastic syndrome, myeloproliferative neoplasms and sickle cell disease, as well as in small cell lung cancer. Central nervous system asset vafidemstat has completed a Phase IIb trial in borderline personality disorder and preparations are underway for Phase III. It is also currently involved in a Phase IIb trial for schizophrenia, and management is preparing for an additional Phase II trial in autism spectrum disorder.
Oryzon Genomics — 8 videos in collection
Oryzon Genomics is a biotech company focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and small-cell lung cancer; Vafidemstat, its CNS product, is in Phase IIa trials in multiple sclerosis, Alzheimer’s disease and aggression. Newer asset ORY-3001 is being developed for certain orphan indications. In this video, the company’s Chief Executive Officer, Carlos Buesa, and Chief Medical Officer Roger Bullock explain the recent R&D progress and expected newsflow.